Innovation

into.blood

Developing

therapies.for

the.treatment

of.rare.diseases

Quince Therapeutics Successfully Completes Acquisition of EryDel S.p.A.

On October 23, 2023, EryDel S.p.A. was acquired by Quince Therapeutics (Nasdaq: QNCX), a Phase 3 biotechnology company that will continue to advance EryDel’s pioneering work to develop a drug delivery technology that leverages a patient’s own biology to deliver rare disease therapeutics.

For more information on Quince, please visit the company’s corporate website at https://quincetx.com/